Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: A retrospective clinical study

Joint Bone Spine

Volumn 80, Issue 3, 2013, Pages 315-319

  Schnabel, Claudia ^a   Jett, Kimberly ^b   Friedman, Jan M ^b   Frieling, Isolde ^c   Kruse, Hans Peter ^c   Mautner, Victor ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Center for Osteoporosis Hamburg Neuer Wall   (Germany)

Author keywords

25 hydroxy vitamin D3 deficiency; Bone mineral density; Cholecalciferol; Dual energy X ray absorptiometry (DXA); Neurofibromatosis 1

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; COLECALCIFEROL; DEOXYPYRIDINOLINE; PARATHYROID HORMONE; BONE DENSITY CONSERVATION AGENT; CALCIFEDIOL; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; LUMBAR SPINE; MALE; NEUROFIBROMATOSIS; OSTEOPENIA; PARATHYROID HORMONE BLOOD LEVEL; RETROSPECTIVE STUDY; URINE LEVEL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; BLOOD; BONE DISEASE; DRUG EFFECT; MIDDLE AGED; PHOTON ABSORPTIOMETRY; TREATMENT OUTCOME; BONE DISEASES; COMPLICATION; DRUG EFFECTS; NEUROFIBROMATOSIS 1;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CALCIFEDIOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84878363998     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.07.010     Document Type: Article

References (36)

1. Huson S.M., Compston D.A.S., Clark P., et al. genetic study of von Recklinghausen Neurofibromatosis in South East Wales 1. prevalence, fitness, mutation rate, and effect of parental transmission of severity. J Med Gen 1989, 26:704-711.
2. Friedman J.M., Birch P.H. Type 1 neurofibromatosis. A descriptive analysis of the disorder in 1728 patients. Am J Med Gen 1997, 70:138-143.
3. Alwan S., Armstrong L., Joe H., et al. Associations of osseus abnormalities in neurofibromatosis 1. Am J Med Gen A 2007, 143A:1326-1333.
4. Brunetti-Pierri N., Doty S.B., Hicks J. Generalized metabolic disease in neurofibromatosis type 1. Mol Gen Metabol 2008, 94:105-111.
5. Friedman J.M. Neurofibromatosis 1: Clinical manifestations and diagnostic criteria. J Child Neuro 2002, 17:548-554.
6. Lammert M., Friedman J.M., Roth H.J., et al. Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis. J Med Genet 2006, 43:810-813.
7. Illés T., Halmai V., de Jonge T., et al. Decreased Bone Mineral Density in Neurofibromatosis-1 Patients with Spinal Deformities. Osteoporos Int 2001, 12:823-827.
8. Kuorilehto T., Pöyhönen M., Bloigu R., et al. Decreased bone mineral density and content in neurofibromatosis type 1: Lowest local values are located in the load-carrying parts of the body. Osteoporos Int 2005, 16:928-936.
9. Lammert M., Kappler M., Mautner V.F., et al. Decreased bone mineral density in patients with neurofibromatosis. Osteoporos Int 2005, 16:1161-1166.
10. Seitz S., Schnabel C., Busse B. High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 2010, 21:119-127.
11. Tucker T., Schnabel C., Hartmann M., et al. Bone health and fracture rate in individuals with NF1. J Med Genet 2009, 46:259-265.
12. Bours Sp, van Geel T.A., Geusens P.P., et al. Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture. J Clin Endocrinol Metab 2011, 96:1360-1367. Epub 2011 Mar 16.
13. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254-1259.
14. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004, 80:1678S-1688S.
15. Markestad T., Halvorsen S., Halvorsen, et al. Plasma concentrations of vitamin D metabolites before and during treatment of vitamin D deficiency rickets in children. Acta Paediatr. Scand 2004, 73:225-231.
16. Holick M.F. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006, 116:2062-2072.
17. Garland C.F., Garland F.C., Shaw E.K., et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989, 18:1176-1178.
18. Garland C., Shekelle R.B., Barrett-Connor E., et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985, 1:307-309.
19. Chen T.C., Holick M.F. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003, 14:423-430.
20. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 1992, 70:2861-2869.
21. Bodiwala D., Luscombe C.J., Liu S., et al. Prostate cancer risk and exposure to ultraviolet rediation: further support for the protective effect of sunlight. Cancer Lett 2003, 192:145-149.
22. Garland F.C., Garland C.F., Gorham E.D., et al. Geographic variation and breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990, 19:614-622.
23. Heaney R.P., Dowell M.S., Hale C.A., et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D3. J Am Coll Nutr 2003, 22:142-146.
24. Chapuy M.C., Preziosi P., Maamer M., et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997, 7:439-443.
25. Viljakainen H.A.T., Natri A.M., Kärkkäinen M., et al. A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolscent girls: a double-blinded randomized placebo-controlled 1-year intervention. J Bone Miner Res 2006, 21:836-844.
26. Dawson-Hughes B., Harris S.S., Krall E.A., et al. Effect of calcium an vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670-676.
27. Baeksgaard L., Andersen K.P., Hyldstrup L Calcium and vitamin D supplementation increases Spinal BMD in healthy postmenopausal women. Osteoporos Int 1998, 8:255-260.
28. DVO-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr, 2006, Dachverband der Deutschsprachigen Osteologischen Fachgesellschaften.
29. Yu X., Chen S., Potter O.L., et al. Neurofibromin and its inactivation of Ras are prerequisites for osteoblasts functioning. Bone 2005, 36:793-802.
30. Yang F.C., Chen S., Robling A.G., et al. Hyperactivation of p21(ras) and PI3K cooperate to after murine and human neurofibromatosis type 1 - haploinsufficient osteoclast functions. J Clin Invest 2006, 116:2880-2891.
31. NIH Consensus Development Conference. Neurofibromatosis. Conference statement. Arch Neurol 1988;45:575-8. Dawson-Hughes B, Hariis SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670-6.
32. Daniele N.D., Carbonelli M.G., Candeloro N., et al. Effect of supplementation of calcium and Vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women: a double-blind, randomized, controlled trial. Pharmacol Res 2004, 50:637-641.
33. Bischoff-Ferrari HA, Giovannucci E., Willett W.C., et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006, 84:18-28.
34. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
35. Dawson-Hughes B., Harris S., Krall E.A., et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670.
36. Delmas P.D. Biochemical markers of bone turnover I: theoretical considerations and clinical use in osteoporosis. Am J Med 1993, 95:11S-16S.